Structure Therapeutics posts Q4 net income; aleniglipron up to 15.3% weight loss in Phase 2

Structure Therapeutics Inc.

2025-FY EPS reported -$0.80

Q4 2025 net income $33.0M vs. net loss of $36.5M in Q4 2024; full-year net loss $141.2M.
Cash, equivalents and investments $1.4B as of Dec 31, 2025, funding through end of 2028.
Aleniglipron Phase 2 ACCESS II: placebo-adjusted weight loss up to 15.3% with 240 mg at 36 weeks.
Phase 3 for aleniglipron expected in H2 2026; topline 44-week data from ACCESS II due Q1 2026.
Oral amylin agonists: ACCG-2671 in Phase 1; ACCG-3535 to enter Phase 1 in H2 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.